Senekjian E K, Frey K W, Stone C, Herbst A L
University of Chicago, Department of Obstetrics and Gynecology, Pritzker School of Medicine, Illinois 60637.
Gynecol Oncol. 1988 Sep;31(1):56-64. doi: 10.1016/0090-8258(88)90269-7.
Of the 76 cases of stage II vaginal clear cell adenocarcinoma reviewed, the lesion involved the vesicovaginal and/or rectovaginal septa (IIc) in 19, the paravaginal/parametrial tissues without extension onto the pelvic sidewall (IIb) in 8, and the subvaginal tissue without paravaginal/parametrial or septal infiltration (IIa) in 36; the substage could not be determined in 13 cases. The three substage groups were similar with regard to maternal hormone history, greatest tumor diameter, depth of invasion, cross-sectional tumor area, location of the lesion in the vagina, predominant histologic pattern and cell type, mitoses, grade, lymph node status, and treatment modality. Actuarial survival rates at 5 and 10 years for all patients with stage II vaginal clear cell adenocarcinoma were 83 and 62%, respectively. The recurrence and survival experiences for the three substage groups were similar. The data available do not suggest any clinical benefit to categorizing cases of stage II vaginal clear cell adenocarcinoma into substages.
在回顾的76例II期阴道透明细胞腺癌病例中，19例病变累及膀胱阴道隔和/或直肠阴道隔（IIc期），8例累及阴道旁/宫旁组织但未延伸至盆腔侧壁（IIb期），36例累及阴道下段组织且无阴道旁/宫旁或隔的浸润（IIa期）；13例无法确定亚分期。这三个亚分期组在母亲激素史、最大肿瘤直径、浸润深度、肿瘤横截面积、阴道病变位置、主要组织学模式和细胞类型、有丝分裂、分级、淋巴结状态及治疗方式方面相似。所有II期阴道透明细胞腺癌患者的5年和10年精算生存率分别为83%和62%。这三个亚分期组的复发和生存情况相似。现有数据未提示将II期阴道透明细胞腺癌病例分为亚分期有任何临床益处。
